ANI Pharmaceuticals announced a $560 million offer to acquire Egetis Therapeutics, expanding its rare disease business. Egetis’ lead product, EMCITATE®, is the first FDA and EU-approved treatment for peripheral thyrotoxicosis linked to MCT8 deficiency, a rare genetic disorder. The acquisition, supported by Egetis’ board and major shareholders, aims to leverage ANI’s resources to maximize EMCITATE®’s $300 million peak sales potential and extend its market exclusivity through 2045. This deal strengthens ANI’s position in rare diseases and adds a new growth driver with durable patent protection.
ANI Pharmaceuticals' acquisition offer for Egetis Therapeutics provides context for readers following health sector stocks. For readers following health-sector US stocks tradable on Pluang, here is the market snapshot as of Nov 05, 2026 18:11 WIB: out of 150 stocks, 85 rose and 56 fell. Among notable movers, ADMA Biologics Inc surged 22.23% to USD 12.81 with a typical hold time of 20 days and 100% sell order activity, contrasting with Adaptive Biotechnologies Corp which gained 5.88% to USD 28.28 and saw 100% buy order activity over a 37-day hold period.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
